Selected Grants
A randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS)
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2024 - 2028ALL ALS Consortium - ASSESS Task Order
ResearchPrincipal Investigator · Awarded by MGH Institute of Health Professionals · 2024 - 2027ALL ALS Consortium - PREVENT Task Order
ResearchPrincipal Investigator · Awarded by MGH Institute of Health Professionals · 2024 - 2027ALL ALS Consortium
ResearchPrincipal Investigator · Awarded by MGH Institute of Health Professionals · 2023 - 2027Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe)
ResearchPrincipal Investigator · Awarded by University of Miami · 2025 - 2025ALSUntangled
ResearchCo Investigator · Awarded by Amyotrophic Lateral Sclerosis Association · 2022 - 2025MDA CReATe
ResearchPrincipal Investigator · Awarded by University of Miami · 2023 - 2025External Relationships
- IAMALS
- KeyQuest Health
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.